Search Results 301-310 of 23204 for B cell lymphomas
... cells without damaging normal cells. Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas.
In-depth. Anaplastic large cell lymphoma · B-cell lymphoma · Burkitt lymphoma · Cancer · Castleman disease · Chronic lymphocytic leukemia.
... B-cell lymphomas who have failed 1-2 prior lines of therapy. The primary objectives are to determine the maximum tolerated dose (MTD) or highest protocol ...
Developing the first genetic test to help guide the diagnosis and treatment of people with diffuse large B-cell lymphoma, the most common type of non-Hodgkin ...
About this study. A multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory large B-cell lymphoma.
... B-cell lymphoma 2 (BCL2) inhibitor. A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma. Jacksonville, Fla ...
Find out more about the symptoms, diagnosis and treatment of this type of non-Hodgkin lymphoma.
Researchers at Mayo Clinic have completed the world's first genome-wide sequencing analysis of peripheral T-cell lymphomas, unlocking the genetic secrets of ...
It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with mantle cell lymphoma.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.